Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

13 febbraio 2022 aggiornato da: Ark Biosciences Inc.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based on the collective clinical and nonclinical data of ziresovir.

The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg, respectively.

A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6 subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

24

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • New Jersey
      • Secaucus, New Jersey, Stati Uniti, 07094
        • Frontage

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Capable of giving written informed consent and complying with study procedures;
  2. Between the ages of 18 and 55 years, inclusive;
  3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg;
  4. Female subjects must have a negative pregnancy test result at screening;
  5. Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, 12-lead ECG, and vital signs;
  6. Willing and being able to adhere to study restrictions and to be confined at the Clinical Research Unit.

Exclusion Criteria:

  1. Clinically significant reported history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;
  2. Poor venous access;
  3. Taken an investigational drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer;
  4. Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the study drug dose;
  5. Major surgery or hospitalization within 6 months prior to screening that in the Investigator's opinion would put the subject or study conduct at risk, or have any scheduled surgery or hospitalization during the study period;
  6. Any condition or finding that in the Investigator's opinion would put the subject or study conduct at risk if the subject were to participate in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: ziresovir

The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.

Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:

  • If administered 60 mL as the study drug dose, follow with approximately 180 mL water.
  • If administered 120 mL as the study drug dose, follow with approximately 120 mL water.
  • If administered 180 mL as the study drug dose, follow with approximately 60 mL water.
Droga: Ziresovir

Planned treatments are:

  • Cohort 1: 300 mg of ziresovir
  • Cohort 2: up to 600 mg of ziresovir
  • Cohort 3: up to 900 mg of ziresovir
Altri nomi:
  • AK0529
Comparatore placebo: placebo

The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.

Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:

  • If administered 60 mL as the study drug dose, follow with approximately 180 mL water.
  • If administered 120 mL as the study drug dose, follow with approximately 120 mL water.
  • If administered 180 mL as the study drug dose, follow with approximately 60 mL water.
Altro: Placebo

Planned treatments are:

  • Cohort 1: 300 mg of placebo
  • Cohort 2: up to 600 mg of placebo
  • Cohort 3: up to 900 mg of placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
numbers of all AEs
Lasso di tempo: through study completion, an average of 22 days
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
through study completion, an average of 22 days
percentages of all AEs
Lasso di tempo: through study completion, an average of 22 days
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
through study completion, an average of 22 days
change from baseline in systolic and diastolic blood pressure
Lasso di tempo: screen/day -1/day 1/day 2/day 3/day4
blood pressure in millimeter of mercury
screen/day -1/day 1/day 2/day 3/day4
change from baseline in pulse rate
Lasso di tempo: screen/day -1/day 1/day 2/day 3/day4
pulse rate in times per minute
screen/day -1/day 1/day 2/day 3/day4
change from baseline in respiratory rate
Lasso di tempo: screen/day -1/day 1/day 2/day 3/day4
respiratory rate in times per minute
screen/day -1/day 1/day 2/day 3/day4
change from baseline in oral temperature
Lasso di tempo: screen/day -1/day 1/day 2/day 3/day4
oral temperature in degree
screen/day -1/day 1/day 2/day 3/day4
change from baseline in Prothrombin time/International Normalized Ratio
Lasso di tempo: screen/day -1/day 2/day4
INR is calculated from the PT and allows for worldwide standardization of results.
screen/day -1/day 2/day4
change from baseline in Thrombin time
Lasso di tempo: screen/day -1/day 2/day4
Thrombin time in seconds
screen/day -1/day 2/day4
change from baseline in activated Partial Thromboplastin time
Lasso di tempo: screen/day -1/day 2/day4
activated Partial Thromboplastin time in seconds
screen/day -1/day 2/day4
change from baseline in Hemoglobin (Hgb) count
Lasso di tempo: screen/day -1/day 2/day4
Hemoglobin (Hgb) in gram per liter
screen/day -1/day 2/day4
change from baseline in Hematocrit (Hct)
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Platelet count
Lasso di tempo: screen/day -1/day 2/day4
Platelet count per liter
screen/day -1/day 2/day4
change from baseline in Red blood cell (RBC) count
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in White blood cell (WBC) count with differential
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Specific gravity from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in pH from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Protein from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Glucose from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Ketones from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Bilirubin from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Blood from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Nitrites from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Leukocytes from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in Urobilinogen from urinalysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
Incidence of abnormal Microscopic urine analysis
Lasso di tempo: screen/day -1/day 2/day4
screen/day -1/day 2/day4
change from baseline in heart rate-corrected QT interval from resting 12-lead ECGs
Lasso di tempo: screen/day -1/day1/day2/day4
ECGs will be performed after the subject has been supine for at least 5 minutes
screen/day -1/day1/day2/day4
change from baseline in heart rate from resting 12-lead ECGs
Lasso di tempo: screen/day -1/day1/day2/day4
ECGs will be performed after the subject has been supine for at least 5 minutes
screen/day -1/day1/day2/day4
change from baseline in QRS intervals from resting 12-lead ECGs
Lasso di tempo: screen/day -1/day1/day2/day4
ECGs will be performed after the subject has been supine for at least 5 minutes
screen/day -1/day1/day2/day4
change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGs
Lasso di tempo: screen/day -1/day1/day2/day4
ECGs will be performed after the subject has been supine for at least 5 minutes
screen/day -1/day1/day2/day4
change from baseline in appearance of U-waves from resting 12-lead ECGs
Lasso di tempo: screen/day -1/day1/day2/day4
ECGs will be performed after the subject has been supine for at least 5 minutes
screen/day -1/day1/day2/day4
Incidence of abnormal physical findings
Lasso di tempo: screen/day -1/day2/day3/day4
full physical examination will be conducted at screening and an abbreviated physical exam will be conducted on Day -1 and Day 2. A symptom-directed physical exam will be conducted on Day 3 and Day 4.
screen/day -1/day2/day3/day4

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
To characterize the drug concentration of ziresovir following single ascending doses by oral administration in healthy adult male and female subjects
Lasso di tempo: 0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose
0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Ark Biosciences Inc.

Investigatori

  • Direttore dello studio: Jimmy Gu, Ark Biosciences

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

24 marzo 2021

Completamento primario (Effettivo)

14 giugno 2021

Completamento dello studio (Effettivo)

22 luglio 2021

Date di iscrizione allo studio

Primo inviato

1 febbraio 2021

Primo inviato che soddisfa i criteri di controllo qualità

4 marzo 2021

Primo Inserito (Effettivo)

9 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 febbraio 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 febbraio 2022

Ultimo verificato

1 febbraio 2022

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • AK0529-3001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

No

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Ziresovir

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Canada

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi